Neurometrix Inc. (NURO) soared 107.17% for July 21

Equities Staff  |

Neurometrix Inc. (NASDAQ: NURO) shares soared 107.17%, or $10.76 per share, to close Wednesday at $20.80. After opening the day at $17.34, shares of Neurometrix fluctuated between $38.67 and $15.75. 89,197,600 shares traded hands an increase from their 30 day average of 14,172,542. Wednesday's activity brought Neurometrix’s market cap to $79,106,456.

Neurometrix is headquartered in Waltham, Massachusetts..

About Neurometrix Inc.

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of disorders involving the nervous system. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of chronic pain that is available over-the-counter.

Visit Neurometrix Inc.’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Neurometrix Inc. and to follow the company’s latest updates, you can visit the company’s profile page here: Neurometrix Inc.’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content